Siolta Therapeutics develops targeted live biotherapeutics using its Precision Symbiotics Platform™ to create therapeutic microbial consortia that address inflammatory diseases. The company combines clinical data and microbial science to target disease-specific mechanisms, aiming to meet the high unmet medical needs in this area.
Funding
$47.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many inflammatory diseases are linked to imbalances in the human microbiome, particularly in early development, and current treatments often address symptoms rather than the underlying microbial causes. Conditions like atopic dermatitis, recurrent bacterial vaginosis, and necrotizing enterocolitis lack preventative therapies that target the root cause of immune dysfunction related to microbial imbalances.
Solution
Siolta Therapeutics develops targeted live biotherapeutic products (LBPs) designed to restore microbial balance and prevent inflammatory diseases. Using their Precision Symbiotics Platform™, they create rationally designed, synergistic combinations of beneficial bacteria that address disease-specific mechanisms of action. Their approach leverages clinical data, bioinformatics, and GMP-manufacturing capabilities to develop microbial consortia that promote healthy immune system development and prevent disease onset. Siolta's LBPs aim to intervene early, particularly in mothers and infants, to prevent conditions where the human microbiota plays a central role in disease prevention.
Target Audience
The primary target audience includes individuals at high risk of inflammatory diseases, particularly newborns and infants at risk of allergic diseases or necrotizing enterocolitis, and women at risk of recurrent bacterial vaginosis.
Features
- Precision Symbiotics Platform™ for rational design of mixed-strain LBPs
- Focus on maternal-infant axis to prevent diseases early in life
- Lead program (STMC-103H) in Phase 2 clinical development for prevention of atopic diseases (atopic dermatitis, food allergy, and asthma)
- Additional programs targeting recurrent bacterial vaginosis (STMC-105) and necrotizing enterocolitis (STMC-106)
- Proprietary human microbiota biobank for strain selection
- In vitro and in vivo therapeutic phenotype screening
- Anaerobic manufacturing expertise
- GMP-manufacturing capabilities